Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
Washington University School of Medicine
Global BioClinical
University of California, Irvine
Bristol-Myers Squibb
VA Office of Research and Development
Masonic Cancer Center, University of Minnesota
SWOG Cancer Research Network
Northwestern University